ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and
Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will reveal enhanced potency and specificity preclinical data for STX-1200, Scribe’s gene
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes Awarded more than $25 million from the California
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic
Scribe received multi-year grant awards from the California Institute for Regenerative Medicine (CIRM) to advance two therapeutic programs from Scribe’s comprehensive, wholly-owned cardiometabolic portfolio Preclinical programs supported by the awards, STX-1200 and STX-1400, have the potential to
Late-breaking oral presentation at EAS Congress 2026 reports up to 90% PCSK9 reduction and up to 68% LDL-C lowering, with the lowest dose achieving >50% LDL-C reduction for >22 months and ongoing, in non-human primates with a clean tolerability profile These data support STX-1150’s recent
ALAMEDA, Calif., May 21, 2026 – Scribe Therapeutics, Inc. (Scribe) a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that it has secured